Open in interactive viewer → charts, metric popovers & call review

Palladyne Sold the Quarter; the Market Is Buying the Bookings

Record revenue and a nine-for-nine Army scorecard, but $2.7 million of net new contracts and a defense budget that just became the company's newest excuse
PDYN · Earnings Call · 2026-11-10

The rearview mirror was flawless

Palladyne AI's third quarter was, on the printed page, the best quarter in its history. Revenue of $8.6 million rose 895% year over year and 48% sequentially, the second consecutive record. Gross margin jumped to 44% from 29%. And the company raised the low end of its full-year guidance to $25 million while reiterating $27 million — roughly 380% to 415% growth over 2025. The revenue line has genuinely turned. Then there is the part that matters more. “We generated record revenue of $8.6 million in the third quarter. That's up 895% from a year ago and up 48% from the second quarter, which itself was a record.” — Benjamin Wolff, President and Chief Executive Officer · 2026-11-10 All true. But the same quarter produced just $2.7 million of net new contract awards, and backlog fell 24% to $18.7 million because the record revenue consumed it faster than new business replaced it. Backlog is now about 2.2 quarters of the current revenue run-rate, and management expects the majority to convert over 12 to 18 months. That is the whole tension in one line: revenue is a rearview mirror, bookings are the windshield. The tape has already decided which it believes. The stock is down 33.5% in the last 90 trading days and 46% off its August 14 peak of $6.61, against a lifetime drawdown of 94% from the 2021 de-SPAC high near $60. And the cost structure has not flexed with the top line — the most recent filed quarter shows a $13 million operating loss on $6 million of revenue, and free cash flow that is still roughly the size of the revenue line itself.

What management quietly stopped saying

Compare the keyword fingerprints of the last two calls, and a strategic retreat becomes visible that the prepared remarks never announce. In the second quarter, Palladyne's most prominent themes included mini bomber (ranked second), Golden Dome (fourth), and Ivy Mass (fifth) — a company hunting large Department of War programs. In the third quarter, all three vanish from the top 30 entirely, replaced by words like defense budget, "federal budget," and "budget uncertainty," along with a distinctly commercial set: Fanuc, "partner led," and Palladyne IQ at the very top.

On Golden Dome, the primary focus for Golden Dome right now is on larger, more exquisite weapon systems... That's not us. We don't play in that sector. But as kind of it trickles down... I think we may have an opportunity to play there, but that's not Golden Dome's priority today.

Benjamin Wolff, President and Chief Executive Officer · 2026-08-06
The reason for the pivot is not subtle. Ben Wolff now opens his own commentary on Washington with a shrug: “everything related to the government that we're doing with SwarmOS has massive opportunity upside, but I can't — my crystal ball at this point is so broken. I can't predict when that's going to actually generate material revenues.” — Benjamin Wolff, President and Chief Executive Officer · 2026-11-10 He repeats the broken-crystal-ball line later on bookings. And he concedes the quarter itself took a hit: some promised funding was “diverted back to the Department of War to support funding for the war effort.” — Benjamin Wolff, President and Chief Executive Officer · 2026-11-10 This is a sharp reversal from August, when the language was about months, not years. “I don't think we're talking about years away, I think we're talking about months away, solicitations come out that start to define requirements that look a lot like what is being trialed in the field with our software.” — Benjamin Wolff, President and Chief Executive Officer · 2026-08-06 Three months later, after an election that changed the funding math, that clock has been stopped and reset. The company is not wrong to be cautious — but investors should note that the change in tone came from the calendar, not from the technology.

The pricing promise that keeps getting cheaper

The genuinely impressive operational fact is real: at Project Convergence Capstone 6, SwarmOS was rated top marks on all nine Army evaluation criteria, letting a single soldier task and manage a multi-vendor drone swarm. The Army paying Palladyne to run exercises rather than Palladyne paying for demos is a real inflection. “A year ago, the revenue that we had from our defense contracts was paying us to advance the capability basically in our labs. Now we're getting paid to actually put it out in the field.” — Benjamin Wolff, President and Chief Executive Officer · 2026-11-10 But watch the monetization slide. In March the guidance was 5% to 10% of platform cost. This quarter it has been narrowed and flattened: 10% of the cost of the drone, full stop — which now explicitly includes $3,000 quadcopters rather than $20,000 aircraft. Widening the aperture sounds like ambition; it also reads like a company that has not yet found the large platform it expected. And the admission is now in its third consecutive quarter in slightly different clothing: “We're not hearing any pushback from direct end users of that pricing structure. Having said that, I have to qualify that by saying we don't have any large contracts buying it yet either.” — Benjamin Wolff, President and Chief Executive Officer · 2026-11-10 In March it was blunter still: “Having said that, I'll remind you that we still have to land our first major customer.” — Benjamin Wolff, President and Chief Executive Officer · 2026-03-05 The new Counter UAS push — SwarmShot, developed with Federal Ammunition and Mossberg — is strategically sensible and sits on top of a global cluster the tape has been actively punishing. The basket of counter-drone names has shed roughly a quarter of its value over the last 90 days and the drone flight test program group is down nearly half over twelve months. This is a crowded, funding-constrained theme, not an uncontested one.

Fanuc is the actual new thing, and the cash clock is real

The Fanuc collaboration is the most defensible new fact in the release. Industrial robots are expensive to program; Palladyne's Scan-to-Path approach lets a robot find a part and generate its own path. Three Fortune 100 use cases were described — grinding hundreds of tack welds, sealing ceiling seams, offline programming of a welding fleet via digital twin. Management was refreshingly honest that “none of these opportunities has resulted in revenue yet.” — Benjamin Wolff, President and Chief Executive Officer · 2026-11-10 But Wolff is explicit that this is where he sees the nearer-term money, because industrial customers do not need an appropriations bill to buy. Which matters, because the balance sheet sets the deadline. Cash and marketable securities of $47 million, no long-term debt, and quarterly operating cash burn of $8.7 million, with full-year burn expected at or slightly above the high end of the $32 million to $36 million range. The company raised $29 million in nine months through its ATM at an average of $6.53 per share and has $12.6 million left — with the stock now well below that average. Price to revenue has fallen from over 80x to the mid-20s as sales arrived, and R&D as a share of revenue has collapsed, which is either operating leverage or a quiet throttle on product investment. The bull case, and it is not a bad one: at roughly $175 million market cap less $47 million of cash, you are paying about $128 million for a business guiding to $27 million of revenue with an Army-validated autonomy stack, a components business shipping record BRAIN flight computers, and a distribution partner in Fanuc that reaches manufacturers Palladyne could never have cold-called. The bear case: bookings of $2.7 million in a quarter, a 10% royalty that no one has yet signed at scale, and a government customer whose budget is now a live political variable. The next two quarters of awards — not the exercise scorecard — are the tell.